Clinical trial
Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to…
NCT00397059 · University of Southern Denmark, Other · Completed
Key facts
| NCT number | NCT00397059 |
|---|---|
| Title | Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism |
| Official title | Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism |
| Lead sponsor | University of Southern Denmark, Other |
| Collaborators | H. Lundbeck A/S Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | Escitalopram |
| Enrollment | 16 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Nov 8, 2006 |
| Last update posted | Feb 6, 2008 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: